Abstract
The development of microneedle (MN)-assisted drug delivery technologies has been highly active for nearly two decades. The microneedle array patch (MAP)-based self-application technology bypasses many of the challenges associated with injectable routes by delivering the therapeutic materials directly into the intradermal space and allowing the release of the active ingredient in a sustained or controlled manner. Different types of biodegradable solid/dissolving MAP and nanoparticle-loaded/coated polymeric MAP or hollow MN have been envisioned for long-acting sustained delivery of therapeutic payloads, aiming for reducing the side effects and administration frequency to improve patient compliance. In this chapter, we covered the different types of MAPs that are loaded with different nano/biotherapeutics for long-acting delivery for a wide range of potential clinical applications. We have outlined the future development scenario for this long-acting MAP delivery system to achieve promising clinical benefits. Finally, it discusses the challenges to realize the full potential of long-acting sustained-release MNs in the clinic.
Original language | English |
---|---|
Title of host publication | Long-acting drug delivery systems: pharmaceutical, clinical, and regulatory aspects |
Publisher | Elsevier Inc. |
Pages | 249-287 |
Number of pages | 39 |
ISBN (Electronic) | 9780128217498 |
DOIs | |
Publication status | Published - 01 Oct 2021 |
Bibliographical note
Publisher Copyright:© 2022 Elsevier Ltd All rights reserved.
Keywords
- Implantable delivery
- Intradermal delivery
- Long-acting therapy
- Microneedle arrays
- Nano/microparticles
- Site-specific delivery
- Sustained-release
- Transdermal delivery
ASJC Scopus subject areas
- General Medicine
- General Biochemistry,Genetics and Molecular Biology